Prof. Dr. med. Marko Kornmann

Onkologische Chirurgie

Kolorektale Chirurgie

Pankreas- und Leberchirurgie

Minimal-invasive OP-Verfahren

Proktologie/chirurgische Endoskopie

Approbation (1994)

Promotion (1995)

Habilitation und Erteilung der Lehrbefugnis für das Fach Chirurgie (2002)

Facharzt für Chirurgie (2003)

Schwerpunkt Viszeralchirurgie (2006)

apl-Professor (2006)

Zusatzweiterbildung: Spezielle Viszeralchirurgie (2011)

Seit 01.01.2009 Leitender Oberarzt der Klinik

Seit 01.10.2020 Stellvertretender Ärztlicher Direktor der Klinik 


Wachstumsfaktoren und Pankreastumoren

  1. Formentini A, Braun F, Fricke H, Henne-Bruns D, Kornmann M. Expression of interleukin-4 and -13 and their receptors in gastric cancer. Hepatogastroenterology, in press. IF 2010: 0,677
  2. Kornmann M, Staib L, Wiegel T, Kron M, Henne-Bruns D, Link KH, Formentini A; Study Group Oncology of Gastrointestinal Tumors (FOGT). Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer. Clin Colorectal Cancer. 2013;12:54-61. IF 2010: 2,632
  3. Wang JC, Thiere M, Henne-Bruns D, Knippschild U, Kornmann M. Inhibition of pancreatic cancer cell growth in vivo using a tetracycline-inducible cyclin D1 antisense expression system. Pancreas. 2013;42:141-8. IF 2010: 2,607
  4. Tian X, Chen G, Zhou S, Henne-Bruns D, Bachem M, Kornmann M. Interactions of pancreatic cancer and stellate cells are mediated by FGFR1-III isoform expression. Hepatogastroenterology. 2012;59:1604-8. IF 2010: 0,677
  5. Hofmann S, Vetter J, Wachter C, Henne-Bruns D, Porzsolt F, Kornmann M. Visual AIDS for multimodal treatment options to support decision making of patients with olorectal cancer. BMC Med Inform Decis Mak. 2012;12:118. IF 2010: 2,231
  6. Formentini A, Henne-Bruns D, Kornmann M. Thymidylate synthase and cyclin D1 protein expression in lymph node negative colorectal cancer: role as prognostic factors? Hepatogastroenterology. 2012;59:1859-64. IF 2010: 0,677
  7. Formentini A, Braun P, Fricke H, Link KH, Henne-Bruns D, Kornmann M. Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer. Int J Colorectal Dis. 2012;27:1369-76. IF 2010: 2,645
  8. Cammerer G, Formentini A, Karletshofer M, Henne-Bruns D, Kornmann M. Evaluation of important prognostic clinical and pathological factors in gastric cancer. Anticancer Res. 2012;32:1839-42. IF 2010: 1,656
  9. Tikidzhieva A, Benner A, Michel S, Formentini A, Link KH, Dippold W, von Knebel Doeberitz M, Kornmann M, Kloor M. Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br J Cancer 2012;106:1239-45. IF 2010: 4,831
  10. Kornmann M, Hebart H, Danenberg K, Goeb R, Staib L, Kron M, Henne-Bruns D, Danenberg P, Link KH. Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: Results of a randomized multicentre trial. Eur J Cancer 2012; 48:1443-51. IF 2010: 4,944
  11. Giehl K, Bachem M, Beil M, Böhm BO, Ellenrieder V, Fulda S, Gress TM, Holzmann K, Kestler HA, Kornmann M, Menke A, Möller P, Oswald F, Schmid RM, Schmidt V, Schirmbeck R, Seufferlein T, von Wichert G, Wagner M, Walther P, Wirth T, Adler G. Inflammation, Regeneration, and Transformation in the Pancreas: Results of the Collaborative Research Center 518 (SFB 518) at the University of Ulm. Pancreas. 2011;40:489-502. IF 2010: 2,607
  12. Kornmann M, Staib L, Wiegel T, Kreuser ED, Kron M, Baumann W, Henne-Bruns D, Link KH. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α. Brit J Cancer 2010;103:1163-72. IF 2010: 4,831
  13. Chen G, Tian X, Liu Z, Zhou S, Schmidt B, Henne-Bruns D, Bachem M, Kornmann M. Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. Brit J Cancer 2010;102:188-95. IF 2010: 4,831
  14. Kalbitz M, Liener U, Kornmann M, Gebhard F, Huber-Lang M. [Evaluation of an objective structured clinical examination (OSCE) in surgery and orthopedics by medical students]. Unfallchirurg 2010;113:726-30. IF 2010: 0,675
  15. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010;9:96.  IF 2010: 3,779
  16. Formentini A, Prokopchuk O, Sträter J, Kleeff J, Grochola LF, Leder G, Henne-Bruns D, Korc M, Kornmann M. Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis 2009;24:57-67. IF 2010: 2,645
  17. Buttenschoen K, Schneider ME, Utz K, Kornmann M, Beger HG, Carli Buttenschoen D. Effect of major abdominal surgery on endotoxin release and expression of Toll-like receptors 2/4. Langenbeck Arch Surg 2009;394:293-302. IF 2010: 1,951
  18. Juchems M, Ernst A, Kornmann M, Barth T, Kramer K, Brambs H-J, Aschoff A. Value of MDCT in preoperative local staging of rectal cancer for predicting the necessity for neoadjuvant radiochemotherapy. RoFo 2009;181:1168-74. IF 2010: 2,473
  19. Siech M, Zhou Z, Zhou S, Bair B, Alt A, Hamm S, Gross H, Mayer J, Beger HG, Tian X, Kornmann M, Bachem MG. Stimulation of stellate cells by injured acinar cells: a model of acute pancreatitis induced by alcohol and fat (VLDL). Am J Physiol Gastrointest Liver Physiol 2009;297:G1163-71. IF 2010: 3,522
  20. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009;28:4065-74. IF 2010: 7,414
  21. Kornmann M, Henne-Bruns D, Porzsolt F. Neoadjuvant treatment of rectal carcinoma: assessment of health care services by physicians and lay persons. (In comments and controveries). J Clin Oncol 2008;26:4866-8. IF 2010: 18,97
  22. Chen G, Wang J, Liu Z, Kornmann M. Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1. Pancreas 2008;37:159-64. IF 2010: 2,607
  23. Kornmann M, Porzsolt F, Henne-Bruns D. Lay assessment of health care services using therapy for rectal cancer as an example. Zentralbl Chir 2008;133:148-55. IF 2010: 0,817
  24. Buttenschoen K, Kornmann M, Berger D, Leder G, Beger HG, Vasilescu C. Endotoxemia and endotoxin tolerance in patients with ARDS. Langenbeck Arch Surg 2008;393:473-8. IF 2010: 1,951
  25. Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, Baumann W, Kreuser ED, Staib L, Link KH. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol 2008;34:1316-21. IF 2010: 2,772
  26. Xi Y, Formentini A, Nakajima G, Kornmann M, Ju J. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncol Rep 2008;19:257-62. IF 2010: 1,686
  27. Liu Z, Neiss N, Zhou S, Henne-Bruns D, Korc M, Bachem M, Kornmann M.  Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth. Cancer Res 2007;67:2712-9. IF 2010: 8,234
  28. Liu Z, Ishiwata T, Zhou S, Maier S, Henne-Bruns D, Korc M, Bachem M, Kornmann M. Human fibroblast growth factor receptor 1-IIIb is a functional fibroblast growth factor receptor expressed in the pancreas and involved in proliferation and movement of pancreatic ductal cells. Pancreas 2007;35:147-57. IF 2010: 2,607
  29. Formentini A, Sander S, Denzer S, Straeter J, Henne-Bruns D, Kornmann M. Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? Int J Colorectal Dis 2007;22:49-55. IF 2010: 2,645
  30. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M, Ju J. Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights 2006;2:113-121. IF 2010: 0
  31. Liu ZB, Yang YM, Qiao QL, Wan YL, Kornmann M, Huang YT. The role of human fibroblast growth factor receptor 1-IIIb isoform in proliferation of pancreatic ductal cells and its effects to mitogen-activated protein kinase. Chinese J Cancer Res 2006;86:2812-6. IF 2010: 0,252
  32. Kornmann M, Link KH, Staib L, Redenbacher M, Kron M, Beger HG, Study Group Oncology of Gastrointestinal Tumors: Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surgery 2005; 242:178-187. IF 2010: 7,474 (dual first authorship)
  33. Hofmann C, Buttenschoen K, Straeter J, Henne-Bruns D, Kornmann M. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy. Anticancer Res 2005; 25:795-804. IF 2010: 1,656
  34. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 2005; 92:921-928. IF 2010: 4,831
  35. Hillenbrand A, Formentini A, Staib L, Sander S, Salonga D, Danenberg K, Danenberg P, Kornmann M. A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy. Eur J Surg Oncol 2004; 30:407-413. IF 2010: 2,772
  36. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Hausler P, Ott K, Behnke D, Staib L, Beger HG, Link KH. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9:4116-4124. IF 2010: 7,338
  37. Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H, Kornmann M. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 2003; 23:5203-5208. IF 2010: 1,656
  38. Kornmann M, Ishiwata T, Matsuda K, Lopez M, Fukahi K, Asano G, Beger HG, Korc M. The IIIc isoform of FGFR-1 is overexpressed in human pancreatic cancer and confers enhanced tumorigenicity to syrian hamster ductal cells. Gastroenterology 2002, 123: 301-313. IF 2010: 12,032
  39. Kornmann M, Link KH, Galuba I, Ott K, Schwabe W, Häusler P, Scholz P, Sträter J, Polat S, Leibl B, Kettner E, Schlichting C, Baumann W, Schramm H, Hecker U, Ridwelski K, Vogt JH, Zerbian KU, Schütze F, Kreuser ED, Behnke D, Beger HG. Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J Gastrointest Surg 2002; 6: 331-337. IF 2010: 2,733
  40. Sträter J, Walczak H, von Müller L, Pukrop T, Kornmann M, Hasel C, Mertens T, Möller P. TRAIL and its receptors in the normal colon epithelium: a putative role in viral defense. Gastroenterology 2002;122:659-666. IF 2010: 12,032
  41. Kornmann M, Lopez ME, Beger HG, Korc M. Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells. Int J Pancreatol 2001;29:87-94. IF 2010: 0
  42. Link KH, Sunelaitis E, Kornmann M, Schatz M, Gansauge F, Leder GH, Formentini A, Staib L, Pillasch J, Beger HG. Regional chemotherapy of non-resectable colorectal liver metastases with mitoxantrone, 5-FU and folinic acid may prolong survival. Cancer, 1469-1474 (2001). IF 2010: 5,131
  43. Kornmann, M., Ishiwata, T., Kleeff, J., Beger, H. G., and Korc, M., Fas and Fas-Ligand expression in human pancreatic cancer. Ann. Surg., 231: 368-379 (2000). IF 2010: 7,474
  44. Kornmann, M., Ishiwata, T., Maruyama, H., Beger, H. G., and Korc, M., Co-expression of Fas and Fas-ligand in chronic pancreatitis: Correlation with apoptosis. Pancreas, 20: 123-128 (2000). IF 2010: 2,607
  45. Kornmann, M., Fakler, H., Butzer, U., Beger, H. G., and Link, K. H., Evaluation of the potential oxaliplatin efficacy for regional chemotherapy of colorectal and pancreatic cancer. Anticancer Res, 20: 3259-3264 (2000). IF 2010: 1,656
  46. Kornmann, M., Link, K. H., Butzer, U., Blatter, J., and Beger, H. G. In vitro concentration response studies of gemcitabine as experimental base for regional chemotherapeutic studies. Eur J Surg Oncol, 26: 583-587 (2000). IF 2010: 2,772
  47. Kleeff, J., Kornmann, M., Sawhney,  H., and Korc, M. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int. J. Cancer, 86: 399-407 (2000). IF 2010: 4,926
  48. Link, K. H., Kornmann, M., Butzer, U., Leder, G., Sunelaitis, E., Pillasch, J., Salonga, D., Danenberg, K. D., Danenberg, P. V., and Beger, H. G. Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer, 89: 288-296 (2000). IF 2010: 5,131
  49. Itakura, J., Ishiwata, T., Shen, B., Kornmann, M., and Korc, M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer, 85: 27-34 (2000). IF 2010: 4,926
  50. Leder, G. H., Pillasch, J., Kornmann, M., Danenberg, P. V., and Link, K. H. Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy. Gan To Kagaku Ryoho, 27: 565-577 (2000). IF 2010: 0
  51. Kornmann, M., Danenberg, K. D., Arber, N., Beger, H. G., Danenberg, P. V., and Korc, M., Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res., 59: 3505-3511 (1999). IF 2010: 8,234
  52. Kornmann M, Tangvoranuntakul P, Korc M. TGF-beta-1 up-regulates cyclin D1 expression in COLO-357 cells, whereas suppression of cyclin D1 levels is associated with down-regulation of the type I TGF-beta receptor. Int. J. Cancer, 83: 247-254 (1999). IF 2010: 4,926
  53. Kornmann, M., Kleeff, J., Debinski, W., and Korc, M., Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer Res., 19(1A): 125-131 (1999). IF 2010: 1,656
  54. Link, K. H., Pillasch, J., Formentini, A., Sunelaitis, E., Leder, G., Safi, F., Kornmann, M., and Beger, H. G. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases. Eur. J. Surg. Oncol., 25: 381-388 (1999). IF 2010: 2,772
  55. Kornmann M, Arber N, Korc M., Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;101:344-52. IF 2010: 15,152
  56. Kornmann, M., Ishiwata, T., Arber, N., Beger, H.G., and Korc, M., Increased cyclin D1 expression in chronic pancreatitis. Pancreas, 17: 158-162 (1998). IF 2010: 2,607
  57. Kornmann, M., Ishiwata, T., Itakura, J., Tangvoranuntakul, P., Beger, H.G., and Korc, M., Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology, 55: 363-369 (1998). IF 2010: 2,538
  58. Kornmann, M., Maruyama, H., Bergmann, U., Tangvoranuntakul, P., Beger, H. G., White, M. F., and Korc, M., Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res., 58: 4250-4254 (1998). IF 2010: 8,234
  59. Ishiwata, T., Kornmann, M., Beger, H.G., and Korc, M., Enhanced fibroblast growth factor-5 expression in stromal and exocrine elements of the pancreas in chronic pancreatitis. Gut, 43: 134-139 (1998). IF 2010: 10,614
  60. Link, K.H., Leder, G., Pillasch, J., Butzer, U., Staib, L., Kornmann, M., Brueckner, U.B., and Beger, H.G., In vitro concentration response studies and in vitro phase II tests as the experimental base for regional chemotherapeutic protocols. Sem Surg Oncol, 14: 189-201 (1998). IF 2010: 0
  61. Kornmann, M., Ishiwata, T., Beger, H.G., and Korc, M., Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene, 15: 1417-1424 (1997). IF 2010: 7,414
  62. Kornmann, M., Link, K.-H., Lenz, H.-J., Pillasch, J., Metzger, R., Butzer, U., Leder, G.H., Weindel, M., Safi, F., Danenberg, K.D., Beger, H.G., and Danenberg, P.V., Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett., 118: 29-35 (1997). IF 2010: 4,864
  63. Ishiwata, T., Bergmann, U., Kornmann, M., Lopez, M., Beger, H. G., and Korc, M., Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas, 15: 367 - 373 (1997). IF 2010: 2,607
  64. Bergmann, U., Funatomi, H., Kornmann, M., Beger, H. G., and Korc, M., Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochem. Biophys. Res. Commun., 220: 886 - 890 (1996). IF 2010: 2,703
  65. Bergmann, U., Funatomi, H., Kornmann, M., Ishiwata, T., Beger, H. G., and Korc, M., Insulin-like growth factor II activates mitogenic signaling in pancreatic cancer cells via IRS-1: in vivo evidence for an islet-cancer cell axis. Int. J. Oncol., 9: 487 - 492 (1996). IF 2010: 2,571
  66. Link, K.H., Kornmann, M., Leder, G.H., Butzer, U., Pillasch, J., Staib, L., Gansauge, F., and Beger, H.G., Regional chemotherapy directed by individual chemosensitivity testing in vitro: A prospective decision-aiding trial. Clin. Cancer Res., 2: 1469-1474 (1996). IF 2010: 7,338
  1. Lemke J, Barth T, Juchems M, Kapapa T, Henne-Bruns D, Kornmann M.  Long-term survival following resection of brain metastases from pancreatic cancer. Anticancer Res 2011;31:4599-603. IF 2010: 1,656
  2. Scheele J, Barth TF, Strassburg J, Juchems M, Kornmann M, Henne-Bruns D. Dermoid cyst of the pancreas. Int J Colorectal Dis 2010;25:415-6. IF 2010: 2,645
  3. Kornmann M, Link KH. Conversion of locally inoperable primary rectal cancer with multiple liver metastases to an option for cure after local down-staging and hepatic arterial infusion chemotherapy. Langenbeck Arch Surg, 2002;387:90-93. IF 2010: 1,951
  1. Kornmann M, Korc M. Fibroblast Growth Factor Receptors and Cancer- Associated Perturbations. In: Lennarz WJ and Lane DD (eds). Academic Press, Waltham, MA. The Encyclopedia of Biological Chemistry; 2013;2:303-8.
  2. Link KH, Kornmann M, Mann M, Bittner R. Multimodale Therapie von Kolon- und Rektumkarzinomen: Qualitätsparameter. Viszeralmedizin 2009;25:105-117.
  3. Kornmann M. Aktuelle chirurgische Therapiestrategien - Kolonkarzinom.
    Verdauungskrankheiten 2007;25:157-62.
  4. Kornmann M, Staib L, Link KH. Aktuelle chirurgische Therapiestrategien - Rektumkarzinom. Verdauungskrankheiten 2007;25:163-70.
  5. M Kornmann, D Henne-Bruns. Kolorektales Karzinom – State of the Art. Kompendium Gastroenterologie 2006;2:2-6.
  6. Kornmann M, Korc M. Fibroblast Growth Factor Receptors and Cancer- Associated Perturbations. In: Lennarz WJ and Lane DD (eds). Academic Press, Waltham, MA. The Encyclopedia of Biological Chemistry 2004;1:112-7.
  • Kornmann M. Zwerchfell. In: Lehrbuch für Chirurgie. Ed. Henne-Bruns D. Duale Reihe, Thieme Verlag, Stuttgart. 2012; 4. Auflage: 288-297.
  • Patent - IL-4 receptor and IL-13 as prognostic markers for colon and pancreas tumors. United States Patent Application 20100111969 (

Deutsche Gesellschaft für Chirurgie (DGC)

Deutsche Gesellschaft für Viszeralchirurgie (DGVC)

European Society of Surgical Oncology (ESSO) A

merican Association of Cancer Research (AACR)

International Colorectal Cancer Club (ICRCC)

Arbeitsgruppe CAO-V - Kolorektales Karzinom

Vorsitzender der FOGT-Studiengruppe (seit 11/2007)

Sekretär des ICRCC (seit 10/2007)